虚血性心疾患治療薬市場レポート：疾患クラス別、薬剤クラス別、地域別、2024年～2032年

虚血性心疾患（IHD）治療薬の世界市場規模は2023年に63億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて3.9%の成長率（CAGR）を示し、市場は2032年までに91億米ドルに達すると予測しています。

虚血性心疾患（IHD）は冠動脈性心疾患としても知られ、酸素と血液の供給を遮断することで心筋に損傷を与える疾患です。虚血性心疾患は、アテロームによる血管の分子変化や冠動脈の突然の閉鎖・狭窄を伴う。この病気は慢性的な胸痛や激しい不快感を特徴とすることが多く、放置すると命にかかわることもあります。IHDの治療には、症例の強さに応じて様々な薬剤が使用されます。例えば、コレステロール改善薬で血液中のコレステロール値を下げれば、血液の凝固傾向を抑えるためにアスピリンが処方され、心拍数を下げて血圧を下げるためにβ遮断薬が利用されます。IHD治療薬にはカルシウム拮抗薬やラノラジンも含まれ、β遮断薬の効果を高め、冠動脈疾患のさらなる進行を防ぐ。

IHD治療のための抗狭心症薬の広範な利用とともに、インターベンション医療処置に対する大衆の傾斜の高まりは、市場成長を促進する重要な要因の一つです。IHD治療薬は、血管形成術、アテレクトミー、バルーン血管形成術などの心臓病治療手技に組み込まれ、健康的な回復を確保し、将来の再発を予防しています。さらに、これらの薬剤を定期的に投与することの利点に関する消費者の意識の高まりも、その需要に大きな影響を与えています。過度の飲酒や喫煙、運動不足といった生活習慣も、心血管疾患の有病率上昇につながっています。さらに、心臓疾患に罹患しやすい老年人口が世界中で増加していることも、IHD治療薬の需要を押し上げています。

本レポートで扱う主な質問

• 虚血性心疾患（IHD）治療薬の世界市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
• COVID-19が世界の虚血性心疾患（IHD）治療薬市場に与えた影響は？
• 疾患クラス別の市場内訳は？
• 薬剤クラス別の市場内訳は？
• 虚血性心疾患（IHD）治療薬の世界市場における主要地域市場は？
• 世界の虚血性心疾患（IHD）治療薬産業のバリューチェーンにおける様々な段階とは？
• 世界の虚血性心疾患（IHD）治療薬産業における主な促進要因と課題は何か？
• 世界の虚血性心疾患（IHD）治療薬業界の構造と主要プレイヤーは？
• 世界の虚血性心疾患（IHD）治療薬業界における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査目的
• 利害関係者
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要産業動向

第5章 虚血性心疾患（IHD）治療薬の世界市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：疾患クラス別

• 狭心症
  • 市場動向
  • 市場予測
• 心筋梗塞
  • 市場動向
  • 市場予測

第7章 市場内訳：薬剤クラス別

• 脂質異常症治療薬
  • 市場動向
  • 市場予測
• カルシウム拮抗薬
  • 市場動向
  • 市場予測
• β遮断薬
  • 市場動向
  • 市場予測
• ACE阻害薬
  • 市場動向
  • 市場予測
• ARB類
  • 市場動向
  • 市場予測
• 血管拡張薬
  • 市場動向
  • 市場予測
• 抗血栓薬
  • 市場動向
  • 市場予測

第8章 市場内訳：地域別

• 北米
  • 市場動向
  • 市場予測
• 欧州
  • 市場動向
  • 市場予測
• アジア太平洋
  • 市場動向
  • 市場予測
• 中東・アフリカ地域
  • 市場動向
  • 市場予測
• ラテンアメリカ
  • 市場動向
  • 市場予測

第9章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第12章 価格分析

第13章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Bayer AG
  • Eli Lilly and Company
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Actelion Pharmaceuticals Ltd.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Merck & Co.
  • Eisai Co., Ltd.

List of Figures

• Figure 1: Global: Ischemic Heart Disease Drugs Market: Major Drivers and Challenges
• Figure 2: Global: Ischemic Heart Disease Drugs Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: Ischemic Heart Disease Drugs Market: Breakup by Disease Class (in %), 2023
• Figure 4: Global: Ischemic Heart Disease Drugs Market: Breakup by Drug Class (in %), 2023
• Figure 5: Global: Ischemic Heart Disease Drugs Market: Breakup by Region (in %), 2023
• Figure 6: Global: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 7: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 8: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 9: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 10: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 11: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 12: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 13: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 14: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 15: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 16: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 17: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 18: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 19: Global: Ischemic Heart Disease Drugs (ARBs) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 20: Global: Ischemic Heart Disease Drugs (ARBs) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 21: Global: Ischemic Heart Disease Drugs (Vasodilators) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 22: Global: Ischemic Heart Disease Drugs (Vasodilators) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 23: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 24: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 25: North America: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 26: North America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 27: Europe: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 28: Europe: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 29: Asia Pacific: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 30: Asia Pacific: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 31: Middle East and Africa: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 32: Middle East and Africa: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 33: Latin America: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 34: Latin America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 35: Global: Ischemic Heart Disease Drugs Industry: SWOT Analysis
• Figure 36: Global: Ischemic Heart Disease Drugs Industry: Value Chain Analysis
• Figure 37: Global: Ischemic Heart Disease Drugs Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Ischemic Heart Disease Drugs Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Disease Class (in Million US$), 2024-2032
• Table 3: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
• Table 4: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 5: Global: Ischemic Heart Disease Drugs Market: Competitive Structure
• Table 6: Global: Ischemic Heart Disease Drugs Market: Key Players

The global ischemic heart disease (IHD) drugs market size reached US$ 6.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.1 Billion by 2032, exhibiting a growth rate (CAGR) of 3.9% during 2024-2032.

Ischemic heart disease (IHD), also known as coronary heart disease, is a condition that damages the heart muscle by interrupting the oxygen and blood supply. It involves molecular changes in the blood vessels or sudden closure and narrowing of coronary arteries by atheroma. The disease is often characterized by chronic chest pain and severe discomfort and can be fatal if left untreated. Various drugs are used to treat IHD depending on the intensity of the case. For instance, if cholesterol-modifying medication decreases cholesterol levels in the blood, then aspirin is prescribed to reduce clotting tendencies of the blood, and beta blockers are utilized to lower the heart rate and decrease blood pressure. IHD drugs also include calcium channel blockers and ranolazine that improve the efficiency of beta blockers and prevent further progression of coronary disease.

The growing inclination of the masses towards interventional medical procedures along with extensive utilization of anti-anginal medications for the treatment of IHD is one of the key factors driving the market growth. IHD drugs are being incorporated in cardiological treatment procedures such as angioplasty, atherectomy and balloon angioplasty to ensure a healthy recovery and prevent relapse in the future. Additionally, rising consumer awareness regarding the benefits of scheduled administration of these drugs is also creating a significant impact on their demand. Lifestyle habits such as excessive alcohol consumption and smoking along with physical inactiveness are also leading to an increasing prevalence of cardiovascular diseases. Furthermore, the expanding population of geriatrics around the globe, who are severely prone to heart ailments, is also boosting the demand for IHD drugs.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global ischemic heart disease (IHD) drugs market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on disease class and drug class.

Breakup by Disease Class:

Angina Pectoris

Myocardial Infarction

Breakup by Drug Class:

Anti-Dyslipidemic Drugs

Calcium Channel Blockers

Beta-Blockers

ACE Inhibitors

ARBs

Vasodilators

Antithrombotic Agents

Breakup by Region:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., and Eisai Co., Ltd.

Key Questions Answered in This Report:

• How has the global ischemic heart disease (IHD) drugs market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global ischemic heart disease (IHD) drugs market?
• What is the breakup of the market based on the disease class?
• What is the breakup of the market based on the drug class?
• What are the key regional markets in the global ischemic heart disease (IHD) drugs industry?
• What are the various stages in the value chain of the global ischemic heart disease (IHD) drugs industry?
• What are the key driving factors and challenges in the global ischemic heart disease (IHD) drugs industry?
• What is the structure of the global ischemic heart disease (IHD) drugs industry and who are the key players?
• What is the degree of competition in the global ischemic heart disease (IHD) drugs industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Ischemic Heart Disease (IHD) Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Disease Class

• 6.1 Angina Pectoris
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Myocardial Infarction
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

• 7.1 Anti-Dyslipidemic Drugs
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Calcium Channel Blockers
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Beta-Blockers
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 ACE Inhibitors
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 ARBs
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Vasodilators
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Antithrombotic Agents
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Europe
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Asia Pacific
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Middle East and Africa
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Latin America
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Bayer AG
  • 13.3.2 Eli Lilly and Company
  • 13.3.3 Novartis International AG
  • 13.3.4 Pfizer, Inc.
  • 13.3.5 Sanofi S.A.
  • 13.3.6 Actelion Pharmaceuticals Ltd.
  • 13.3.7 Baxter International Inc.
  • 13.3.8 Boehringer Ingelheim International GmbH
  • 13.3.9 Bristol-Myers Squibb Company
  • 13.3.10 Amgen Inc.
  • 13.3.11 F. Hoffmann-La Roche AG
  • 13.3.12 GlaxoSmithKline Plc
  • 13.3.13 Merck & Co.
  • 13.3.14 Eisai Co., Ltd.